Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43800   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-000482-36
    Sponsor's Protocol Code Number:LUM001-201
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2013-05-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2013-000482-36
    A.3Full title of the trial
    A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase 2 study to investigate use of LUM001 as a treatment for Primary Biliary Cirrhosis (PBC). This is a chronic and slowly progressive cholestatic liver disease of autoimmune aetiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure.
    A.3.2Name or abbreviated title of the trial where available
    CLARITY STUDY
    A.4.1Sponsor's protocol code numberLUM001-201
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT01904058
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorLumena Pharmaceuticals, Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportLumena Pharmaceuticals, Inc.
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationLumena Pharmaceuticals, Inc.
    B.5.2Functional name of contact pointVice President, Operations
    B.5.3 Address:
    B.5.3.1Street Address12531 High Bluff Drive, Suite 110
    B.5.3.2Town/ citySan Diego, CA
    B.5.3.3Post code92130
    B.5.3.4CountryUnited States
    B.5.4Telephone number448447745347
    B.5.6E-mailckennedy@lumenapharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLUM001
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLUM001
    D.3.9.2Current sponsor codeLUM001
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number5 to 20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary biliary cirrhosis (PBC) is a chronic and slowly progressive cholestatic liver disease of autoimmune etiology characterized by injury of the intrahepatic bile ducts that may eventually lead to liver failure. Affected individuals are usually in their fifth
    to seventh decades of life at time of diagnosis, and 90% are women.
    E.1.1.1Medical condition in easily understood language
    PBC is an autoimmune disease of the liver marked by slow progressive destruction of the small bile ducts of the liver, with the intralobular ducts (Canals of Hering) affected early in the disease.
    E.1.1.2Therapeutic area Body processes [G] - Metabolic Phenomena [G03]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.1
    E.1.2Level LLT
    E.1.2Classification code 10036680
    E.1.2Term Primary biliary cirrhosis
    E.1.2System Organ Class 100000004871
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study in subjects with primary biliary cirrhosis (PBC) undergoing daily dosing over a 13-week period is:

    To evaluate the effect of LUM001 in combination with ursodeoxycholic acid (UDCA) versus UDCA alone on the reduction of pruritus associated with PBC.
    E.2.2Secondary objectives of the trial
    The secondary objectives of this study are:

    To evaluate the effect of LUM001 in combination with UDCA versus UDCA alone on alkaline phosphatase levels associated with PBC.

    To evaluate the effect of LUM001 in combination with UDCA versus UDCA alone on liver enzymes associated with PBC.

    To evaluate the safety and tolerability of LUM001 in combination with UDCA during 13 weeks of therapy in patients with PBC.

    The exploratory objectives of this study are:

    To explore the effect of LUM001 in combination with UDCA versus UDCA alone on other biochemical markers associated with PBC.

    To explore the effect of LUM001 in combination with UDCA versus UDCA alone on quality of life using a PBC-specific health related quality of life (PBC-40) instrument.

    To explore the effect of LUM001 in combination with UDCA versus UDCA alone on sleep using the Medical Outcomes Study Sleep Scale (MOS-Sleep).
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male or female subjects between the ages of 18-80 years, inclusive.

    2. Diagnosis of PBC [consistent with the American Association for the Study of Liver Disease (AASLD, Section 16.3) Practice Guidelines Practice Guidelines; (Lindor, Gershwin, Poupon, Kaplan, Bergasa, & Heathcote, 2009), as demonstrated by the
    documented history of at least 2 of the following diagnostic factors:
    a. History of elevated alkaline phosphatase (ALP) levels;
    b. Presence of anti-mitochondrial antibodies (AMA) with a titer ≥1:40;
    c. Liver biopsy consistent with PBC if a biopsy has been performed;
    d. For patients who are AMA negative, a liver biopsy diagnostic for PBC.

    3. A previous ultrasound (or equivalent imaging modality) of the biliary tree that excludes biliary obstruction and overt malignancy within 12 months of the screening visit.

    4. An average daily score > 4.0 on the Adult Itch Reported Outcome (Adult ItchROTM) questionnaire (maximum possible daily score of 10), for each of two consecutive weeks in the screening period using the eDiary.

    5. Taking ursodeoxycholic acid (UDCA) for at least 6 months (stable dose for ≥ 3 months) prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months prior to Day 0).

    6. If using any of the following medications, must be on a stable dose for the period indicated and expected to remain on the same dose and regimen throughout the treatment period:
    a. For 30 days prior to screening: rifampin, antihistamines, opiate antagonists;
    b. For 90 days prior to screening: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs).

    7. Females of childbearing potential must have a negative serum pregnancy test [β human chorionic gonadotropin (β-hCG)] during screening and negative urine pregnancy test at the baseline visit.

    8. Sexually active females must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use an effective method (≤ 1% failure rate) of contraception during the trial. Effective methods of contraception are considered to be:
    a. Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection) provided subject has been on stable therapy for at least 3 months; or
    b. Barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or
    c. Intrauterine device (IUD); or
    d. Vasectomy (partner).

    9. Ability to read and understand English or Spanish in order to use the study-related questionnaires.

    10. Ability to read the text on the eDiary screen.

    11. Must be willing and able to use an eDiary daily for a minimum of 20 weeks.

    12. Must digitally accept the licensing agreement in the eDiary software at the outset of the study.

    13. Must complete at least 10 eDiary Adult ItchRO reports (AM or PM) during each of two consecutive weeks of the screening period prior to randomization (maximum possible reports = 14 per week).

    14. Access to phone for scheduled calls from study site.

    15. Must agree to comply with the study protocol and provide written informed consent.
    E.4Principal exclusion criteria
    1. History or presence of other concomitant significant liver disease as assessed by the Investigator including:
    a. Hepatitis B infection (HBsAg positive);
    b. Hepatitis C infection (antibody positive); patients with a positive antibody test will be eligible if there is documented history of negative HCV RNA and not previously treated for HCV;
    c. Any other cholestatic liver disease [e.g., primary sclerosing cholangitis (PSC)];
    d. Alcoholic liver disease;
    e. Proven overlap autoimmune hepatitis;
    f. Proven nonalcoholic steatohepatitis (NASH).

    2. Presence of advanced clinical complications of PBC or clinically significant hepatic decompensation, including:
    a. History of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score ≥ 15;
    b. Hepatic encephalopathy;
    c. Hepatorenal syndrome (type I or II) or screening serum creatinine >2.00 mg/dL (177 μmol/L).

    3. Total bilirubin > 2 x ULN at screening.

    4. ALT or AST > 5 x ULN at screening.

    5. History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine [e.g., inflammatory bowel disease, celiac disease or gastric bypass procedures (gastric lap band is acceptable)].

    6. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget’s disease).

    7. Known history of human immunodeficiency virus (HIV) infection.

    8. The anticipated need for a surgical procedure within 20 weeks from randomization.

    9. Any female who is pregnant or lactating or who is planning to become pregnant within 20 weeks of randomization.

    10. Cancer within 5 years of screening, except for basal or squamous cell carcinoma of the skin or in situ cervical carcinoma that has been treated with no evidence of recurrence.

    11. History of alcohol abuse, or other substance abuse within 1 year prior to screening.

    12.Administration of the following medications:
    a. For 12 months prior to randomization: rituximab;
    b. For 90 days prior to randomization: azathioprine, mercaptopurine,
    mycofenolate, hydroxychloroquine, leflunomide, anti-TNF therapies,
    tocilizumab;
    c. For 60 days prior to randomization: ≥ 7.5 mg prednisone (or equivalent); (topical, inhaled, or short course therapy for intercurrent illness are permitted), bezafibrate/fenofibrate;
    d. For 30 days prior to randomization: methotrexate, bile acid resins (such as cholestyramine), colchicine.

    13. Receipt of an investigational drug, biologic, or medical device within 30 days prior to screening, or 5 half-lives of the study agent, whichever is longer.

    14. History of noncompliance with medical regimens, unreliability, mental instability or incompetence that could compromise the validity of informed consent or lead to noncompliance with the study protocol.

    15.Any other conditions or abnormalities which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the subject, or interfere with the subject participating in or completing the study.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy endpoint is change from baseline to Week 13 in pruritus as measured by the weekly sum score using the Adult ItchRO instrument. For this instrument, the subject indicates the severity of their itching in the morning and in the evening each day during screening and during the study period for 13 weeks. The
    daily score will be assessed as outlined in Section 8.4.1 of the protocol and will have a range from 0-10, with the higher score indicating increasing itch severity. The Adult ItchRO weekly sum score will be the sum of each daily score over a study week, and is thought to provide a
    measure of the weekly burden of itch.

    For the change from baseline calculation in the Adult ItchRO weekly sum score, baseline is defined as the weekly sum of the daily scores in the week consisting of the 7 days immediately prior to Day 0. The Week 13 Adult ItchRO weekly sum score is defined as the weekly sum of the daily scores of the week consisting of the 7 days immediately prior to the Week 13 visit. Missing data on the daily score will be imputed using the average daily Adult ItchRO score from that week.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 0 and week 13.
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints include:

    Change from baseline in pruritus as measured by Adult ItchRo weekly sum scores at Weeks 4 and 8.

    Change from baseline in pruritis as measured by the AdultItchRO average daily scores at weeks 4, 8 and 13. The average daily score for a 7-day period will be the sum of the daily scores for the 7-day period divided by the number of days the dairy is completed in that 7-day period

    Change from baseline in alkaline phosphatase at Weeks 4, 8 and 13.

    Change from baseline in 5-D Itch score at Weeks 4, 8 and 13.

    Change from baseline in fasting serum bile acid level at Weeks 4, 8 and 13.

    Change from baseline in bile acid synthesis [serum 7α-hydroxy-4-cholesten-3-one (7αC4)] at Weeks 4, 8 and 13.

    Exploratory efficacy endpoints include:

    Pruritus response rates as measured by Adult ItchRO at Weeks 4, 8 and 13.

    Change from baseline for other biochemical markers of cholestasis (total and conjugated bilirubin) at Weeks 4, 8, and 13.

    Change from baseline for other liver enzymes (ALT, AST) at Weeks 4, 8 and 13.

    Change from baseline for lipid biomarkers (total cholesterol, LDL-C) at Weeks 4 and 13.

    Change from baseline for PBC-40 at Weeks 4, 8 and 13.

    Change from baseline for MOS-Sleep at Weeks 4 and 13.

    Patient Impression of Change (PIC) at Week 13.

    Patient Global Therapeutic Benefit (PGTB) assessment at Week 13.

    In addition, the following exploratory evaluations will be conducted if the results of the primary and secondary analyses illustrate a difference between drug and placebo treated subjects.

    Change from baseline for measures of bile acid synthesis (FGF-19 and FGF-21) at Weeks 4 and 13.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Timepoints for evaluation of each secondary and exploratory endpoint are reported in Section E.5.2
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months4
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 40
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 20
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 20
    F.4.2.2In the whole clinical trial 60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Following the completion of the study, subjects will return to standard care.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-06-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-07-08
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-04-09
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA